Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1979 1
1980 13
1981 2
1982 6
1983 3
1984 1
1985 7
1986 4
1987 13
1988 13
1989 15
1990 12
1991 13
1992 17
1993 16
1994 22
1995 23
1996 14
1997 26
1998 28
1999 31
2000 47
2001 43
2002 46
2003 66
2004 82
2005 121
2006 113
2007 119
2008 145
2009 146
2010 221
2011 202
2012 241
2013 311
2014 374
2015 425
2016 430
2017 528
2018 568
2019 792
2020 924
2021 1147
2022 1369
2023 1340
2024 594

Text availability

Article attribute

Article type

Publication date

Search Results

9,528 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Among authors: luo s. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, Luo S, Qin Y, Guo Q, Bai Y, Ling Y, Yang J, Yan Z, Yang L, Tang Y, He Y, Zhang L, Liang X, Niu Z, Zhang J, Mao Y, Guo Y, Peng B, Li Z, Liu Y, Wang Y, Zhou H; ORIENT-16 Investigators. Xu J, et al. Among authors: luo s. JAMA. 2023 Dec 5;330(21):2064-2074. doi: 10.1001/jama.2023.19918. JAMA. 2023. PMID: 38051328 Clinical Trial.
Phytochemicals in Chronic Disease Prevention.
Sun J, Luo S, Deng J, Yang H. Sun J, et al. Among authors: luo s. Nutrients. 2023 Nov 27;15(23):4933. doi: 10.3390/nu15234933. Nutrients. 2023. PMID: 38068791 Free PMC article.
Roles and functions of IAV proteins in host immune evasion.
Rashid F, Xie Z, Li M, Xie Z, Luo S, Xie L. Rashid F, et al. Among authors: luo s. Front Immunol. 2023 Dec 13;14:1323560. doi: 10.3389/fimmu.2023.1323560. eCollection 2023. Front Immunol. 2023. PMID: 38152399 Free PMC article. Review.
Different evasion strategies in multiple myeloma.
Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y, Luo S. Wang C, et al. Among authors: luo s. Front Immunol. 2024 Feb 23;15:1346211. doi: 10.3389/fimmu.2024.1346211. eCollection 2024. Front Immunol. 2024. PMID: 38464531 Free PMC article. Review.
ANGPTL4 binds to the leptin receptor to regulate ectopic bone formation.
Hu H, Luo S, Lai P, Lai M, Mao L, Zhang S, Jiang Y, Wen J, Zhou W, Liu X, Wang L, Huang M, Hu Y, Zhao X, Xia L, Zhou W, Jiang Y, Zou Z, Liu A, Guo B, Bai X. Hu H, et al. Among authors: luo s. Proc Natl Acad Sci U S A. 2024 Jan 2;121(1):e2310685120. doi: 10.1073/pnas.2310685120. Epub 2023 Dec 26. Proc Natl Acad Sci U S A. 2024. PMID: 38147550
9,528 results